Verdict: Mixed
FACTS (prices_daily / FMP quote, after close 10/5): close 7.06 (9/16) -> 14.98 (10/5) = +112% in 13 sessions. Catalyst bar 9/17: +11% (7.06->7.84) on 2.66M vs ~0.9M avg. Legs: 9/22 +17% (3.3M), 9/24 +19% (4.0M), 9/29 +14% (4.7M), 10/5 +21% to 14.98 on 7.64M (largest volume of the run), high 15.48, closed near high. Open 10/5 12.50 vs prior close 12.35 (no gap). 52w high 17.58, 50MA 8.08 (~85% above), ~61% above 20MA, 20-day ADR ~10.5%.
Catalyst (real): Sep 15-16 2026 Ginkgo Datapoints signed an agreement with Lilly TuneLab to provide discovery data generation (small-molecule ADME + antibody developability testing) to TuneLab companies. https://s28.q4cdn.com/823357996/files/doc_news/2026/Sep/16/Ginkgo-Datapoints-x-TuneLab-Announcement.pdf . 10/5: call volume 10,531 vs ~1,055 avg (+898%) https://www.gurufocus.com/news/9110384/ginkgo-bioworks-dna-surges-21-on-heavy-options-activity-following-lilly-tunelab-partnership . Theme: AI-bio data-generator rotation (TWST also signed TuneLab deal, TXG/TWST/PACB leaders).
Fundamentals (10-Q 6/30/26): Q2 revenue $20.2M (down ~48% YoY), wider losses; cash+securities $302.2M; ~60.7M shares (52.3M A + 8.4M B) -> mkt cap ~$0.9-1.0B. Analyst consensus Reduce, avg PT ~$6.33 (MarketBeat 9/30).
SUPPLY FLAG (hard): $100M ATM with Allen & Co (Sept 2025); 3.7M shares sold for $34.6M net through 6/30/26; ~$65.4M remains = ~4.4M shares at $15 (~7% dilution) that can be sold into this rally. https://www.sec.gov/Archives/edgar/data/0001830214/000162828026054298/dna-20260630.htm
Verdict: real catalyst but small (data-services contract, not disclosed size) vs a +112% move on a shrinking business, with call-option frenzy and an ATM overhang -> mixed. Inference: late-innings name per the 54-name theme study (near-zero-revenue names ripping in the last month).